Arecor given grant for diabetes drug combination platform

A privately-held UK company has picked up a £1 million ($1.3 million) grant for its work on a formulation platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care.

Arecor, in collaboration with the Manchester Institute of Biotechnology (MIB), has received the grant from government agency Innovate UK, to make possible the sophisticated combination of two or more existing therapeutic products for diabetes treatment, in a single liquid ready-to-use format.

Using robotics and ultra-high speed analytics, the platform, named Arestat, could potentially answer problems with conventional formulation approaches caused by the incompatibility of compounds that have different properties and therefore require different environments in order to be active and stable.